Plain-English translation of NCT07202884 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help women with stress urinary incontinence—urine leakage that happens during movement, exercise, or coughing—especially those who are overweight or have obesity. The trial will compare the medication to a placebo (a dummy pill with no active ingredient) to measure how well and safely this treatment works. About 1,000 women will participate across two separate but similar studies.
Stress urinary incontinence is a common and bothersome problem for many women, and current treatment options are limited. This medication represents a new approach that researchers hope could offer relief for women dealing with this condition, particularly those who are overweight or living with obesity.
You likely qualify if…
You likely don't qualify if…
You would take a daily tablet (either the new medication or a placebo) for about 12 weeks, with several clinic visits for check-ins and symptom tracking. The entire study lasts roughly 58 weeks from your initial screening appointment through a final safety follow-up. You'll be monitored to see how well the treatment works and to watch for any side effects.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States